<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882228</url>
  </required_header>
  <id_info>
    <org_study_id>HL_ENTL_401</org_study_id>
    <nct_id>NCT04882228</nct_id>
  </id_info>
  <brief_title>Phase 4 Study to Evaluate Efficacy and Safety of Entelon Tab.150mg in Patients With Chronic Venous Disease(CVD)</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Active Controlled, Parallel Group, Non-inferiority Phase 4 Study to Evaluate Efficacy and Safety of Entelon Tab.150mg in Patients With Chronic Venous Disease(CVD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a multi-center, double-blind, randomized, active controlled , parallel&#xD;
      design, non-inferiority phase 4 study to evaluate the efficacy and safety of Entelon 150mg in&#xD;
      278 patients with chronic venous disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to prove that Entelon tab. 150mg is non-inferior in clinical efficacy and&#xD;
      safety compared to Venitol tab. for 8 weeks in patients suffering from chronic venous&#xD;
      disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CIVIQ-20 questionnaire score change</measure>
    <time_frame>8week(Visit 4)</time_frame>
    <description>Change at week 8 of treatment with the drug from baseline(day 0) in CIVIQ-20 questionnaire score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CIVIQ-20 questionnaire score change</measure>
    <time_frame>4week(Visit 3)</time_frame>
    <description>Change at week 4 of treatment with the drug from baseline(day 0) in CIVIQ-20 questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AVVQ questionnaire score change</measure>
    <time_frame>4week(Visit 3), 8week(Visit 4)</time_frame>
    <description>Change at week 4, 8 of treatment with the drug from baseline(day 0) in AVVQ questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100mm VAS score change of leg heaviness, leg pain, leg cramps</measure>
    <time_frame>4week(Visit 3), 8week(Visit 4)</time_frame>
    <description>Change at week 4, 8 of treatment with the drug from baseline(day 0) in symptoms of leg heaviness, leg pain, leg cramps thorugh 100mm VAS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous clinical severity score change</measure>
    <time_frame>4week(Visit 3), 8week(Visit 4)</time_frame>
    <description>change at week 4, 8 of treatment with the drug from baseline(day 0) in Venous clinical severity score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the circumference of the leg due to edema</measure>
    <time_frame>8week(Visit 4)</time_frame>
    <description>change at week 8 of treatment with the drug from baseline(day 0) in leg circumference</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">278</enrollment>
  <condition>Chronic Venous Disease</condition>
  <arm_group>
    <arm_group_label>Entelon Tab.150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Venitol tab.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entelon Tab.150mg</intervention_name>
    <description>twice daily for 8 weeks</description>
    <arm_group_label>Entelon Tab.150mg</arm_group_label>
    <other_name>Vitis Vinifera Seed Dreid Extract 150mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venitol Tab.</intervention_name>
    <description>twice daily for 8 weeks</description>
    <arm_group_label>Venitol tab.</arm_group_label>
    <other_name>Purified and Micronized Flavonoid Fraction 500mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Venitol Tab.</intervention_name>
    <description>twice daily for 8 weeks (with Entelon Tab.150mg. It is for the masking.)</description>
    <arm_group_label>Entelon Tab.150mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Entelon Tab.150mg</intervention_name>
    <description>twice daily for 8 weeks(with Venitol Tab. It is for the masking.)</description>
    <arm_group_label>Venitol tab.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 19 years ≤ age ≤ 80 years&#xD;
&#xD;
          2. Those who are diagnosed as CEAP Classification Class 1 ~ Class 3&#xD;
&#xD;
          3. Those who have the Venous Duplex ultrasonography result at least one of the following&#xD;
&#xD;
               -  reflux more than 1 second in Femoral vein or Popliteal vein&#xD;
&#xD;
               -  reflux more that 0.5 second in GSV or SSV or Accessory saphenous vein or&#xD;
                  perforating vein or calf vein&#xD;
&#xD;
          4. Those who have completed the washout period as following until the baseline, including&#xD;
             the screening period&#xD;
&#xD;
               -  Analgesic, corticosteroids, anti-inflammatory drugs: at least 2 weeks&#xD;
&#xD;
          5. Those who provide written consent voluntarily to participate in this clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who must wear compression stockings&#xD;
&#xD;
          2. Those who have obstruction of the peripheral arteries of the lower extremities&#xD;
&#xD;
          3. Those who have asymptomatic varicose veins&#xD;
&#xD;
          4. Those who have acute deep vein thrombosis&#xD;
&#xD;
          5. Those who have frequent lower extremity pain due to neuropathy&#xD;
&#xD;
          6. Varicose vein surgery patient or prospective person (if surgery was done more than 1&#xD;
             year prior to the time of screening, recruitment is possible)&#xD;
&#xD;
          7. Those who have systemic disease that causes edema or thrombosis&#xD;
&#xD;
          8. Those who have a history of malignant tumors within 5 years prior to the time of&#xD;
             screening&#xD;
&#xD;
          9. Those who have severe renal dysfunction at the time of screening (serum creatinine ≥ 2&#xD;
             x upper limit of normal)&#xD;
&#xD;
         10. Those who have severe liver dysfunction at the time of screening (AST or ALT ≥ 3 x&#xD;
             upper limit of normal)&#xD;
&#xD;
         11. Those who are required to receive diuretics, analgesics, corticosteroids,&#xD;
             anti-inflammatory drugs, or contraindications that may affect the outcome of this&#xD;
             clinical trial during the clinical trial period&#xD;
&#xD;
         12. Those who have a history of significant mental illness, alcohol abuse&#xD;
&#xD;
         13. Patients who have an allergy to investigational product or any of its excipients&#xD;
&#xD;
         14. Patients who participated in other clinical trials within 12 weeks prior to the date&#xD;
             of screening&#xD;
&#xD;
         15. Pregnant or lactating woman&#xD;
&#xD;
         16. Those who do not agree to use an effective method of contraception&#xD;
&#xD;
         17. Individual considered by the investigator to be ineligible for study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nahyun Kang</last_name>
    <phone>82-2-3489-6298</phone>
    <email>nahyun.kang@hanlim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bundang Seoul University Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taeseung Lee, Ph.D</last_name>
      <email>tslee@snubh.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

